Vaxcyte Starts Phase 1/2 Study Evaluating VAX-31 for Invasive Pneumococcal Disease in Adults

 -- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic --

-- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 --

-- VAX-31 is Designed to Provide Coverage for Approximately 95% of Invasive Pneumococcal Disease Circulating in the U.S. Adult Population -

https://www.biospace.com/article/releases/vaxcyte-doses-first-participants-in-phase-1-2-clinical-study-evaluating-vax-31-for-the-prevention-of-invasive-pneumococcal-disease-in-adults/